SANTA BARBARA, Calif.,
July 18, 2013 /PRNewswire/ -- VG Life
Sciences, (OTC Pink: VGLS) a biotechnology company, announces
alterations in its corporate management and management
structure.
Interim CEO & President
John Tynan has been named Interim
CEO & President of VG Life Sciences, inc, effective
immediately. Mr. Tynan started TynanGroup, Inc. in 1991 and grew it
to successful company as a leader in real estate development
services across the country, overseeing more than $4 billion of construction. TynanGroup was on INC
Magazine's list of the fasting growing companies and today includes
a host of sister companies including MedBridge Development Company,
LLC and Anchor Point IT Solutions. Prior to starting TynanGroup, he
was Vice President for Hyatt Development Corporation where he
oversaw $1.5 Billion project
expenditures and over 9,000 people. Mr. Tynan has a BS in Civil
Engineering from the University of
Illinois and a MBA in finance from DePaul University. "My focus is on achieving
specific goals to increase shareholders' value and support our
exceptional research team," said Tynan. Haig Keledjian will stay on as Chairman of the
Board and VP of Intellectual Property and Product Development.
For more information on the goals and direction of the company
as well as the new management structure of VG Life Sciences, please
see the July 18th, 2013
investor letter, which can be downloaded from the company site and
viewed here.
About VG Life Sciences Inc.
Santa Barbara, California-based VG Life
Sciences Inc., formerly known as Viral Genetics, is a biotechnology
company focused on discovering and developing drug therapies for
cancer, infectious diseases, and autoimmune disorders. VGLS
controls over 50 US and international patents and pending patents
protecting its exclusive biotech platform technologies. For more
information, visit www.vglifesciences.com.
CONTACT:
Alexandria Sumner, Corporate
Communications
VG Life Sciences, Inc.
Phone: (805) 679-6763
Email: Alex@vglifesciences.com
SOURCE VG Life Sciences, Inc.